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Dear Editor,
We read with interest the recently published review published by Mende entitled "Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes" 1 . It is of interest that there are isolated incidents of deterioration in renal function associated with the use of SGLT-2 inhibitors in clinical trials 2, 3 . We agree with Mende and other publications 4 providing experimental evidence that SGLT-2 inhibitors are nephroprotective rather than nephrotoxic.
We have examined changes in renal function in our routine real-world clinic practice database before and during treatment with dapagliflozin. Dapagliflozin is recommended by NICE as monotherapy or in combination with other antidiabetic medications including insulin in type 2 diabetes 5 . In our practice, dapagliflozin was added to concomitant antidiabetic medications including insulin and GLP-1 agonists.
We undertook a prospective audit of patients who had been initiated on dapagliflozin and had undergone at least one follow-up visit. A paired t-test was performed to examine changes in serum creatinine and estimated glomerular filtration rate (eGFR) before and during treatment with dapagliflozin. We identified 148 patients (63% male) with a mean age of 57.8 ± 9.0 years who had received a mean duration of treatment of 15.6 ± 8.7 months with dapagliflozin. We observed no significant changes in pre-and post-treatment serum creatinine (76 ± 18 vs. were also observed as shown in Table 1 . In those individuals with a follow-up of less than 6 months (n ¼ 23), eGFR decreased from 87 ± 20 to 80 ± 20 mL/min per 1.73 m 2 , p ¼ .02).
In conclusion, no significant change in renal function was observed in our cohort (n ¼ 148), who had been treated with dapagliflozin for a mean duration of 15.6 months. Our finding supported the idea that SGLT2 inhibitors are not nephrotoxic. Larger studies with long-term follow-up are warranted to confirm the nephroprotective effect of SGLT2 inhibitors.
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